An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.

PHASE3CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Advanced Stage Parkinson's Disease
Interventions
DRUG

Pardoprunox

12-42 mg/day

Trial Locations (87)

Unknown

S308.3.007 Site # 220, La Jolla

S308.3.007 Site # 211, San Francisco

S308.3.007 Site # 214, Fort Lauderdale

S308.3.007 Site # 218, Gainsville

S308.3.007 Site # 213, Tampa

S308.3.007 Site # 219, Augusta

S308.3.007 Site # 221, Chicago

S308.3.007 Site # 216, Kansas City

S308.3.007 Site # 224, Lexington

S308.3.007 Site # 212, East Lansing

S308.3.007 Site # 217, St Louis

S308.3.007 Site # 222, Durham

S308.3.007 Site # 210, Tledo

S308.3.007 Site # 215, Houston

S308.3.007 Site # 223, Birmingham

S308.3.007 Site # 100, Buenos Aires

S308.3.007 Site # 101, Buenos Aires

S308.3.007 Site # 102, Buenos Aires

S308.3.007 Site # 103, Buenos Aires

S308.3.007 Site # 106, Buenos Aires

S308.3.007 Site # 107, Buenos Aires

S308.3.007 Site # 109, Buenos Aires

S308.3.007 Site # 105, Córdoba

S308.3.007 Site # 104, Mar del Plata

S308.3.007 Site # 108, Santa Fe

S308.3.007 Site # 114, Alto da Glória

S308.3.007 Site # 113, Belo Horizonte

S308.3.007 Site # 112, Campinas

S308.3.007 Site # 116, Marília

S308.3.007 Site # 111, Porto Alegre

S308.3.007 Site # 118, Porto Alegre

S308.3.007 Site # 117, Ribeirão Preto

S308.3.007 Site # 119, Salvador

S308.3.007 Site # 115, Sâo Paulo

S308.3.007 Site # 110, São Paulo

S308.3.007 Site # 125, São Paulo

S308.3.007 Site # 123, Plovdiv

S308.3.007 Site # 120, Sofia

S308.3.007 Site # 121, Sofia

S308.3.007 Site # 122, Sofia

S308.3.007 Site # 124, Sofia

S308.3.007 Site # 136, Calgary

S308.3.007 Site # 137, Greenfield Park

S308.3.007 Site # 133, Halifax

S308.3.007 Site # 132, Markham

S308.3.007 Site # 130, Montreal

S308.3.007 Site # 134, Ottawa

S308.3.007 Site # 138, Peterborough

S308.3.007 Site # 135, Sainte-Anne

S308.3.007 Site # 139, Toronto

S308.3.007 Site # 131, Windsor

S308.3.007 Site # 140, Santiago

S308.3.007 Site # 141, Santiago

S308.3.007 Site # 143, Santiago

S308.3.007 Site # 142, Valdivia

S308.3.007 Site # 151, Bogotá

S308.3.007 Site # 152, Bogotá

S308.3.007 Site # 153, Bogotá

S308.3.007 Site # 154, Bogotá

S308.3.007 Site # 150, Medellín

S308.3.007 Site # 160, Riga

S308.3.007 Site # 172, Kaunas

S308.3.007 Site # 170, Vilnius

S308.3.007 Site # 171, Vilnius

S308.3.007 Site # 184, Bellavista Callao

S308.3.007 Site # 180, Lima

S308.3.007 Site # 181, Lima

S308.3.007 Site # 182, Lima

S308.3.007 Site # 183, Lima

S308.3.007 Site # 193, Kazan'

S308.3.007 Site # 190, Moscow

S308.3.007 Site # 194, Moscow

S308.3.007 Site # 197, Moscow

S308.3.007 Site # 191, Saint Petersburg

S308.3.007 Site # 192, Saint Petersburg

S308.3.007 Site # 195, Saint Petersburg

S308.3.007 Site # 198, Saint Petersburg

S308.3.007 Site # 196, Yaroslavl

S308.3.007 Site # 204, Dnipro

S308.3.007 Site # 206, Kharkiv

S308.3.007 Site # 201, Kyiv

S308.3.007 Site # 202, Kyiv

S308.3.007 Site # 205, Lviv

S308.3.007 Site # 203, Poltava

S308.3.007 Site # 208, Simferopol

S308.3.007 Site # 200, Vinnytsia

S308.3.007 Site # 207, Zaporozhya

All Listed Sponsors
lead

Solvay Pharmaceuticals

INDUSTRY

NCT00407095 - An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations. | Biotech Hunter | Biotech Hunter